These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26652963)

  • 1. [Hypolipidemic and antihypertensive therapy in diabetic patients in the Czech Republic: notes on the VZP (General Health Insurance Company) Data].
    Šnejdrlová M; Češka R; Janíčková-Žďárská D; Honěk P; Dušek P; Pavlík T; Kvapil M
    Vnitr Lek; 2015 Nov; 61(11 Suppl 3):3S30-7. PubMed ID: 26652963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of incidence and prevalence of cardiovascular risk factors and evaluation of their control in epidemiological survey in the Czech Republic.
    Chmelík Z; Vaclová M; Lánská V; Laštůvka J; Vrablík M
    Cent Eur J Public Health; 2020 Jun; 28(2):114-119. PubMed ID: 32592555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of inertia with lipid-lowering treatment in patients with type 2 diabetes mellitus.
    García Díaz E; Ramírez Medina D; Morera Porras ÓM; Cabrera Mateos JL
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Apr; 66(4):223-231. PubMed ID: 30541682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease].
    Pérez A; González Blanco C; Hernández-Presa MÁ; Chaves J
    Endocrinol Nutr; 2011; 58(6):283-90. PubMed ID: 21641286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of fenofibrate in clinical practice.
    Zambon A; Cusi K
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cardiovascular risk profile in 40-year old men and 50-year old women in the Czech Republic: results of a cross-sectional survey].
    Vrablík M; Chmelík Z; Lánská V
    Vnitr Lek; 2014 Nov; 60(11):991-7. PubMed ID: 25600047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future perspectives of the pharmacological management of diabetic dyslipidemia.
    Patti AM; Giglio RV; Papanas N; Rizzo M; Rizvi AA
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):129-143. PubMed ID: 30644763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study.
    Kaasenbrood L; Poulter NR; Sever PS; Colhoun HM; Livingstone SJ; Boekholdt SM; Pressel SL; Davis BR; van der Graaf Y; Visseren FL;
    Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):213-21. PubMed ID: 27174798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CONTROVERSIAL ISSUES IN THE TREATMENT OF DYSLIPIDEMIAS IN PATIENTS WITH DIABETES MELLITUS.
    Parhofer KG
    Rev Invest Clin; 2018; 70(5):237-243. PubMed ID: 30307445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.
    Anabtawi A; Moriarty PM; Miles JM
    Curr Cardiol Rep; 2017 Jul; 19(7):62. PubMed ID: 28528456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statin utilization patterns for the primary prevention of cardiovascular events: a retrospective study in patients with diabetes mellitus in Hong Kong.
    Lee VW; Ho IC; Chan WS; Tam KY; Lee KK
    Am J Cardiovasc Drugs; 2008; 8(3):199-205. PubMed ID: 18533740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug therapy of diabetic dyslipidemia: do the statins suffice?
    Mooradian AD
    Am J Ther; 2015; 22(1):87-8. PubMed ID: 23728161
    [No Abstract]   [Full Text] [Related]  

  • 16. Lipid-lowering drug adherence and combination therapy effects on gastrointestinal cancer in patients with dyslipidemia without diabetes: a retrospective cohort study in South Korea.
    Han KT; Kim S
    BMC Cancer; 2022 Feb; 22(1):156. PubMed ID: 35135497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus.
    Wanner C; Krane V
    Kidney Blood Press Res; 2011; 34(4):209-17. PubMed ID: 21691123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role for combination therapy in diabetic dyslipidemia.
    Warraich HJ; Wong ND; Rana JS
    Curr Cardiol Rep; 2015 May; 17(5):32. PubMed ID: 25894802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
    Pérez A
    Endocrinol Nutr; 2010 Dec; 57(10):457-9. PubMed ID: 20688585
    [No Abstract]   [Full Text] [Related]  

  • 20. [Dyslipemia in diabetics treated with statins. Results of the DYSIS study in Spian].
    Millán J; Alegría E; Guijarro C; Lozano JV; Vitale GC; González-Timón B; González-Juanatey JR
    Med Clin (Barc); 2013 Nov; 141(10):430-6. PubMed ID: 23246165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.